Nitrofurantoin

Introduction Overview

Generic Name

nitrofurantoin

Brand Name

Macrobid

Dosage Form

oral capsule and oral suspension

Drug Class

Urinary anti-infectives

Pharmacokinetics

Absorption:
Nitrofurantoin is well absorbed from the gastrointestinal tract after oral administration, with peak plasma concentrations typically reached within 30 minutes to 2 hours. It should be taken with food to enhance absorption and reduce gastrointestinal irritation. Absorption can be compromised by concurrent administration of antacids containing magnesium trisilicate which may decrease bioavailability. The oral suspension form also allows for adequate systemic exposure especially in pediatric populations.

Distribution:
After absorption, nitrofurantoin distributes primarily to the urinary tract, achieving high concentrations in urine which is critical for its therapeutic effect in urinary tract infections (UTIs). Plasma protein binding is relatively moderate to high, around 40-50%. Tissue distribution outside of the urinary tract is limited, with low concentrations detected in cerebrospinal fluid and other tissues, reflecting its targeted urinary tract site of action.

Metabolism:
Nitrofurantoin undergoes minimal hepatic metabolism. The majority of the dose is either excreted unchanged or undergoes partial reduction to reactive intermediates. The liver plays a minor role, but nitrofurantoin can cause hepatic side effects in susceptible individuals, suggesting some hepatic involvement in its biotransformation.

Elimination:
The primary route of elimination is renal excretion, with 40-50% of the administered dose excreted unchanged in urine. This renal excretion is critical to its antibacterial efficacy against urinary pathogens. Nitrofurantoin has a short elimination half-life of approximately 20 minutes to 1 hour, necessitating multiple daily dosing to maintain effective urinary concentrations. Impaired renal function significantly reduces elimination and urinary concentrations, contraindicating its use in patients with severe renal impairment.

Dosage Forms

Available Dosage Forms:
- Oral capsule (100 mg) - Typically formulated as dual-release capsules combining immediate and sustained release nitrofurantoin to maintain effective urinary levels.
- Oral suspension (25 mg/5 mL) - indicated primarily for pediatric patients.

Dosages for Adults and Adolescents:
- For acute uncomplicated cystitis: Dual-release capsules, 100 mg orally twice daily for 7 days.
- For cystitis prophylaxis: Regular release formulation, 50-100 mg orally once daily at bedtime.

Specific Patient Populations:
- Pediatric patients aged 1 month or older can receive oral suspension at 5-7 mg/kg/day divided into 4 doses or dual-release capsules (for those over 12 years) at 100 mg twice daily for 7 days.
- Use in elderly requires caution due to renal function considerations.
- Contraindicated in patients with severe renal impairment due to risk of toxicity and reduced efficacy.
- Avoid use in neonates under 1 month of age.
- Avoid use in late pregnancy (last 2 to 4 weeks).
Pharmacists should ensure proper measuring devices are used for suspensions, and administration should be with food to reduce gastrointestinal side effects.

Mechanism Of Action

Nitrofurantoin exerts its antibacterial effect through multiple mechanisms, predominantly by disrupting the bacterial enzyme systems involved in the metabolism, cell wall synthesis, and protein synthesis. After being reduced by bacterial nitrofuran reductases, it forms reactive intermediates that attack bacterial DNA, ribosomal proteins, and other macromolecules, leading to cell death.

This multi-targeted oxidative mechanism results in broad bactericidal activity against many Gram-positive and Gram-negative organisms most commonly implicated in urinary tract infections, such as Escherichia coli, Enterococcus species, and Staphylococcus saprophyticus. Because it damages several bacterial processes simultaneously, the development of bacterial resistance to nitrofurantoin is relatively low compared to single-target antibiotics.

On a cellular level, the drug interferes with vital enzymatic functions by producing highly reactive intermediates inside bacterial cells which causes irreversible damage to DNA and ribosomal proteins, thereby inhibiting bacterial replication and function. This contrasts with antibiotics targeting single enzymes or pathways, such as beta-lactams or fluoroquinolones.

Clinical studies support nitrofurantoin's efficacy specifically localized to the urinary tract due to its rapid excretion in urine and its bactericidal mechanism. This localization spares systemic microbiota exposure, reducing collateral damage and antibiotic resistance pressure elsewhere. Comparative research shows nitrofurantoin remains effective against many multidrug-resistant urinary pathogens, justifying its place as a first-line agent for uncomplicated UTIs.

Pharmacological Actions

Broad-spectrum bactericidal activity against common urinary pathogens, including Escherichia coli, Staphylococcus saprophyticus, and Enterococcus species.
Generation of reactive intermediates upon reduction by bacterial nitrofuran reductase enzymes, causing DNA and protein damage.
Inhibition of bacterial enzymatic processes involved in metabolism, protein synthesis, and cell wall synthesis.
Localization of activity primarily in the urinary tract due to high urinary excretion of unchanged drug.
Rapid urinary bactericidal concentrations with short systemic half-life.
Low propensity for bacterial resistance due to multiple molecular targets.
Minimal systemic antimicrobial effects, limiting impact on normal flora in other body sites.
Adjunct prophylactic effect in recurrent urinary tract infections by maintaining suppressive urinary concentrations.
Mild anti-inflammatory effects reported in some experimental models but not the primary mechanism.
Dual-release formulation provides sustained urinary levels improving efficacy and tolerability.
Renal excretion-dependent clearance makes dosing adjustments necessary in renal impairment.
Poor activity against non-urinary pathogens due to limited tissue penetration outside the urinary tract.
Contraindicated in late pregnancy due to potential risk of hemolytic anemia in the newborn, linked to oxidative stress.

Therapeutic Or Clinical Uses

Treatment of acute uncomplicated urinary tract infections (UTIs) caused by susceptible bacteria.
Prophylactic use for prevention of recurrent urinary tract infections, especially in female patients with history of recurrent cystitis.
Empiric therapy for uncomplicated cystitis due to favorable activity against common uropathogens.
Alternative treatment in patients allergic to beta-lactams or trimethoprim-containing antibiotics.
Pediatric use for UTIs in children over 1 month of age with appropriate dosing.
First-line oral antibiotic choice in non-pregnant adults with normal renal function for cystitis treatment.
Potential use in outpatient management of lower urinary tract infections to reduce systemic antibiotic exposure.
Limited use as part of combination therapy in complicated UTI cases when susceptibility allows.
Avoided in patients with complicated urinary tract infections due to limited tissue penetration.
Used cautiously in elderly patients due to renal clearance considerations.
Off-label uses may include prophylaxis in patients with neurogenic bladder under specialist supervision.
Useful for community-acquired UTIs where local resistance to other antibiotics is high.

Side Or Adverse Effects

Gastrointestinal disturbances such as nausea, vomiting, and mild diarrhea.
Headache and dizziness reported in some patients during therapy.
Allergic reactions including rash, urticaria, and in severe cases, anaphylaxis.
Pulmonary reactions including acute pneumonitis and chronic pulmonary fibrosis especially with long-term use.
Peripheral neuropathy manifesting as numbness, tingling, or pain in extremities, particularly in elderly or those with renal impairment.
Hepatic side effects including asymptomatic elevation of liver enzymes, hepatitis, cholestatic jaundice, and very rarely, liver failure.
Hemolytic anemia, particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Lupus-like syndrome characterized by joint pain, fever, and rash in rare cases.
Potential for superinfection with resistant organisms or fungi due to alteration of normal flora.
Common transient side effects include vaginal itching or discharge.
Urine discoloration (brownish color) which is harmless but may alarm patients.
Rare central nervous system effects including confusion and hallucinations mainly in elderly.
Photosensitivity reactions have occasionally been reported.
Long-term use associated with increased risk of pulmonary and hepatic toxicity.
Serious hypersensitivity reactions may necessitate immediate discontinuation.

Precautions

Avoid use in patients with severe renal impairment (creatinine clearance < 60 mL/min) due to risk of toxicity and reduced efficacy.
Do not use during last 2 to 4 weeks of pregnancy due to risk of hemolytic anemia in the fetus or newborn.
Caution in patients with G6PD deficiency given risk of hemolysis.
Use cautiously in patients with pre-existing liver disease owing to potential hepatotoxicity.
Consider dose adjustment or avoidance in elderly patients with declining renal function.
Avoid concomitant use with antacids containing magnesium trisilicate that reduce nitrofurantoin absorption.
Patients with anemia, diabetes, vitamin B deficiency, or electrolyte imbalance require close monitoring during therapy.
Avoid use in neonates and infants under 1 month due to increased risk of hemolytic anemia.
Inform patients to take with food to minimize gastrointestinal adverse effects.
Monitor for signs of pulmonary toxicity during prolonged therapy.
Monitor liver function tests in patients receiving prolonged treatment.
Warn patients about potential urine discoloration to prevent unnecessary concern.
Use caution in patients with debilitating diseases where adverse effects may be more pronounced.
Advise patients to report any new neurological symptoms promptly.
Adjust or discontinue therapy if allergic reactions or severe side effects develop.

Warnings

Contraindicated in patients with severe renal impairment due to lack of efficacy and potential toxicity.
Avoid use in the last trimester of pregnancy (final 2 to 4 weeks) because of risk of hemolytic anemia in neonates.
Risk of severe pulmonary reactions including interstitial pneumonitis and pulmonary fibrosis, particularly with long-term use.
Potential for serious hepatic toxicity including hepatitis and cholestatic jaundice.
Possibility of peripheral neuropathy that may be irreversible if not recognized early.
May cause hemolytic anemia in patients with G6PD deficiency.
Serious hypersensitivity reactions including anaphylaxis can occur rarely.
Long-term prophylaxis should be accompanied by periodic monitoring of liver and pulmonary function.
Use with caution in elderly and debilitated patients due to increased risk of adverse reactions.
Use carefully in patients with anemia or other hematologic disorders.
Not effective against complicated urinary tract infections.
Misuse may contribute to the development of bacterial resistance.
Patients should inform healthcare providers of all concurrent medications to prevent interactions.
Immediate medical attention required if signs of severe allergic reactions or respiratory symptoms develop.
Pregnancy Category B but contraindicated in late pregnancy.

Contraindication

Known hypersensitivity or allergy to nitrofurantoin or any of its components.
Severe renal impairment (creatinine clearance < 60 mL/min) or anuria and oliguria.
History of jaundice or liver dysfunction related to nitrofurantoin use.
Last 2 to 4 weeks of pregnancy (due to risk of hemolytic anemia in fetus/neonate).
Infants younger than 1 month of age.
Patients with significant anemia or glucose-6-phosphate dehydrogenase (G6PD) deficiency without close medical supervision.
Complicated urinary tract infections requiring systemic therapy with broader spectrum antibiotics.
Concurrent use with antacids containing magnesium trisilicate that markedly reduce its absorption.
Use contraindicated when urine cultures identify pathogens resistant to nitrofurantoin.
Patients with severe debilitating diseases without careful risk-benefit assessment.
Patients who cannot tolerate oral medication or those with malabsorption syndromes affecting nitrofurantoin uptake.
Known pulmonary or hepatic hypersensitivity to nitrofurantoin.
Use contraindicated in acute bacterial pyelonephritis where tissue penetration is inadequate.
Concomitant use with other drugs predisposing to hemolysis may be contraindicated.
Contraindicated as a viral infection treatment since it lacks antiviral activity.

Drug Interactions

Antacids containing magnesium trisilicate reduce the absorption and bioavailability of nitrofurantoin, decreasing its efficacy.
Probenecid and other urine alkalinizers may reduce urinary excretion of nitrofurantoin, lowering its therapeutic concentrations.
Concurrent use with other nephrotoxic drugs may increase the risk of renal toxicity.
Medications causing hemolysis, such as sulfonamides, may have additive hemolytic effects in G6PD-deficient patients when combined with nitrofurantoin.
Drugs that alter urine pH (e.g., acetazolamide) may affect nitrofurantoin elimination and activity.
No significant interactions with oral contraceptives reported, but clinicians should monitor for breakthrough bleeding.
Potential interference with certain urine glucose tests, leading to false-positive results.
Concurrent use with antibiotics that also target urinary pathogens should be monitored for additive toxicity or antagonism.
Interaction with drugs inducing hepatic enzymes is minimal due to limited hepatic metabolism.
Use with caution when combined with other drugs causing peripheral neuropathy (e.g., isoniazid, phenytoin).
No notable interactions with common antihypertensive or diabetic medications documented.
Potential increased risk of CNS adverse effects with concomitant use of CNS depressants though evidence is limited.
Monitoring advised when used alongside other drugs that cause pulmonary toxicity.
Interactions with vitamins or herbal supplements have not been well studied but should be disclosed to healthcare providers.
Patients should inform all healthcare providers about their nitrofurantoin therapy when starting new medications.

Preparations Of The Drug

Macrobid capsules: 100 mg nitrofurantoin in a dual-release formulation combining immediate and sustained release components.
Oral suspension: nitrofurantoin monohydrate macrocrystals in 25 mg/5 mL concentration for pediatric use.
Generic nitrofurantoin products are also available with similar dosing forms including macrocrystalline capsules and suspensions.
Formulations designed to optimize urinary concentration while minimizing systemic exposure and adverse effects.
Dual-release formulations allow twice daily dosing improving patient compliance versus older four times daily regimens.
Suspension formulation includes flavoring agents to improve palatability for children.
Packaging may include dosing syringes or cups with oral suspension to ensure accurate dosing.
Tablets and standard capsules are generally not used due to enhanced gastrointestinal side effects compared to capsules.
Specialty compounding options may be available for unique dosing needs but are uncommon.
Storage recommended at room temperature away from moisture and heat to maintain stability.
No injectable or parenteral formulations commercially available owing to the drug’s specific urinary tract target.
Each product contains excipients specific to formulation type, requiring consultation of product inserts in case of allergy concerns.
Some formulations labeled for short-term treatment only; long-term prophylaxis requires medical supervision and patient monitoring.
Availability includes branded Macrobid and generic nitrofurantoin macrocrystals preparations.
Manufactured under strict regulatory guidelines ensuring potency and quality for urinary anti-infective indications.